Gonadotropin Therapy for Mini-Puberty Induction in Male Infants With Hypogonadotropic Hypogonadism
Authors' conclusion
This systematic review provides unique evidence supporting the efficacy of gonadotropins for induction of mini-puberty. However, the reliability and generalizability are limited due to disparate data and treatment modality variation.
Study context
- Population
- Male infants with congenital hypogonadotropic hypogonadism (CHH), 12 with Kallmann syndrome; 11 studies from 7 countries; median age at treatment initiation 4.2 months (range, 0.25–57 months); follow-up 3 to 10 years
- Participants
- 71 infants11 studies
- Comparison
- Gonadotropin therapy in male infants with CHH
- Continuous subcutaneous infusionn = 35
- Subcutaneous injectionn = 36
- Outcome
- Mini-puberty related outcomes:
- Penile length
- Inhibin B
- Testicular descent
Methodological detailsPRISMA, Cochrane Risk of Bias for Non-Randomised Studies of Interventions
- PRISMA
- Cochrane Risk of Bias for Non-Randomised Studies of Interventions
Pooled result
As reported in the abstract
Mini-puberty related outcomes with gonadotropins (modalities combined)
- Statistically significant increase in penile length and inhibin B concentration
- P = .0007
- Partial or full testicular descent
- 73% (n = 62)
Original publication
Gonadotropin Therapy for Mini-Puberty Induction in Male Infants With Hypogonadotropic Hypogonadism. J Clin Endocrinol Metab. Published 14 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →